Cynosure Group LLC Has $294,000 Stake in CorVel Co. (NASDAQ:CRVL)

Cynosure Group LLC increased its holdings in shares of CorVel Co. (NASDAQ:CRVL) by 131.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,643 shares of the business services provider’s stock after acquiring an additional 1,500 shares during the quarter. Cynosure Group LLC’s holdings in CorVel were worth $294,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the business. Fifth Third Bancorp increased its holdings in shares of CorVel by 45.9% in the fourth quarter. Fifth Third Bancorp now owns 321 shares of the business services provider’s stock valued at $36,000 after purchasing an additional 101 shares during the last quarter. Jones Financial Companies Lllp acquired a new position in CorVel in the 4th quarter valued at about $37,000. US Bancorp DE raised its holdings in CorVel by 225.4% in the 4th quarter. US Bancorp DE now owns 384 shares of the business services provider’s stock valued at $43,000 after acquiring an additional 266 shares during the period. GAMMA Investing LLC lifted its position in CorVel by 175.2% during the fourth quarter. GAMMA Investing LLC now owns 432 shares of the business services provider’s stock worth $48,000 after acquiring an additional 275 shares during the last quarter. Finally, CIBC Private Wealth Group LLC boosted its holdings in shares of CorVel by 300.0% during the fourth quarter. CIBC Private Wealth Group LLC now owns 480 shares of the business services provider’s stock worth $53,000 after acquiring an additional 360 shares during the period. Institutional investors own 51.36% of the company’s stock.

Insider Activity

In related news, Director Steven J. Hamerslag sold 10,000 shares of the firm’s stock in a transaction on Thursday, February 6th. The stock was sold at an average price of $123.48, for a total value of $1,234,800.00. Following the transaction, the director now owns 314,000 shares in the company, valued at approximately $38,772,720. This trade represents a 3.09 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Jeffrey J. Michael sold 10,477 shares of the company’s stock in a transaction dated Thursday, February 20th. The stock was sold at an average price of $116.45, for a total transaction of $1,220,046.65. Following the sale, the director now directly owns 568,310 shares of the company’s stock, valued at $66,179,699.50. This represents a 1.81 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 32,200 shares of company stock worth $3,824,115. Corporate insiders own 47.57% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, StockNews.com lowered CorVel from a “buy” rating to a “hold” rating in a research note on Thursday, March 13th.

CorVel Price Performance

CRVL stock opened at $111.12 on Friday. The business’s fifty day moving average price is $112.34 and its two-hundred day moving average price is $114.70. The stock has a market capitalization of $5.71 billion, a price-to-earnings ratio of 65.37 and a beta of 1.06. CorVel Co. has a fifty-two week low of $76.20 and a fifty-two week high of $128.61.

CorVel (NASDAQ:CRVL) last issued its quarterly earnings data on Tuesday, February 4th. The business services provider reported $0.46 earnings per share for the quarter. CorVel had a net margin of 10.12% and a return on equity of 32.22%.

CorVel Profile

CorVel Corporation provides workers’ compensation, auto, liability, and health solutions. It applies technology, including artificial intelligence, machine learning, and natural language processing to enhance the managing of episodes of care and the related health care costs. The company also offers network solutions services, including automated medical fee auditing, preferred provider management and reimbursement, retrospective utilization review, facility claim review, professional review, pharmacy, directed care, clearinghouse, independent medical examination, and inpatient medical bill review services, as well as Medicare solutions.